BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zeuzem S. Treatment Options in Hepatitis C. Dtsch Arztebl Int 2017;114:11-21. [PMID: 28143635 DOI: 10.3238/arztebl.2017.0011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Zeuzem S. [Chronic hepatitis C : Standard treatment and remaining challenges]. Internist (Berl) 2018;59:528-35. [PMID: 29696303 DOI: 10.1007/s00108-018-0429-y] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Peiffer KH, Zeuzem S. [Treatment of hepatitis C infections in the era of direct-acting antivirals (DAAs)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2022. [PMID: 35006288 DOI: 10.1007/s00103-021-03481-z] [Reference Citation Analysis]
3 Wörmann B. The Treatment of Hepatitis C- An Introduction to the Use of New Medicines. Dtsch Arztebl Int 2017;114:9-10. [PMID: 28143634 DOI: 10.3238/arztebl.2017.0009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
4 Durmashkina E, Zeuzem S, Sarrazin C. [Treatment of parenterally transmittable viral hepatitis]. Internist (Berl) 2022. [PMID: 35303130 DOI: 10.1007/s00108-022-01287-y] [Reference Citation Analysis]
5 Westermann C, Wendeler D, Nienhaus A. Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents. J Occup Med Toxicol 2021;16:34. [PMID: 34429125 DOI: 10.1186/s12995-021-00320-4] [Reference Citation Analysis]
6 Prell T, Dirks M, Arvanitis D, Braun D, Peschel T, Worthmann H, Schuppner R, Raab P, Grosskreutz J, Weissenborn K. Cerebral patterns of neuropsychological disturbances in hepatitis C patients. J Neurovirol. 2019;25:229-238. [PMID: 30610739 DOI: 10.1007/s13365-018-0709-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Vyas BH, Darji NH, Rana DA, Vyas KY, Malhotra SD. Impact of newer direct-acting antiviral drugs based on quality-adjusted life years: A prospective pharmacoeconomic study in hepatitis C patients. Perspect Clin Res 2021;12:76-82. [PMID: 34012903 DOI: 10.4103/picr.PICR_123_19] [Reference Citation Analysis]
8 Westermann C, Wendeler D, Nienhaus A. Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents. J Occup Med Toxicol 2018;13:16. [PMID: 29849741 DOI: 10.1186/s12995-018-0197-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
9 Wörns MA, Galle PR, Zeuzem S, Schirmacher P, Manns M, Vogel A. Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk. Dtsch Arztebl Int 2017;114:597-602. [PMID: 28927498 DOI: 10.3238/arztebl.2017.0597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
10 Dultz G, Müller T, Petersen J, Mauss S, Zimmermann T, Muche M, Simon KG, Berg T, Zeuzem S, Hüppe D, Böker K, Wedemeyer H, Welzel TM; Leberstiftungs-GmbH Deutschland. Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry. Drugs Aging 2018;35:843-57. [PMID: 30084012 DOI: 10.1007/s40266-018-0572-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
11 Boushi E, Cheha K, Hedar N, Almokdad R, Alassi MW, Kakaje A. Sofosbuvir/ledipasvir safety and efficacy for HCV patients with haemodialysis and liver cirrhosis: a small retrospective study. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00150-3] [Reference Citation Analysis]
12 Zhao N, Xie R, Zhao X, Zhao H, Jia B, Zhang Y, Luo L, Huang Z, Li J, Wang X, Yan H, He B, Xie H, Ren Q, Cui Y. Safety, Tolerability and Pharmacokinetics of Yimitasvir Phosphate Capsule, a Novel Oral Hepatitis C Virus NS5A Inhibitor, in Healthy Chinese Volunteers. Clin Drug Investig 2019;39:671-81. [PMID: 31079356 DOI: 10.1007/s40261-019-00791-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]